LFG
ARCT icon

Larson Financial Group’s Arcturus Therapeutics ARCT Stock Holding History

Larson Financial Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$13 – 3439
2025
Q2 		$13 Hold
1
– – ﹤0.01% 3262
2025
Q1 		$11 Hold
1
– – ﹤0.01% 3052
2024
Q4 		$17 Hold
1
– – ﹤0.01% 2750
2024
Q3 		$23 Buy
+1
New +$21 ﹤0.01% 2669
2022
Q4 		– Sell
-340
Closed -$5K – 1507
2022
Q3 		$5K Hold
340
– – ﹤0.01% 941
2022
Q2 		$5K Hold
340
– – ﹤0.01% 860
2022
Q1 		$9K Hold
340
– – ﹤0.01% 673
2021
Q4 		$13K Buy
+340
New +$13.9K ﹤0.01% 613

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Larson Financial Group's ARCT Position: Q3 2025 in Review

Larson Financial Group sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 1 share — an estimated $13 sold.

Larson Financial Group first reported a position in ARCT in Q4 2021 and held it in 8 quarters. The position peaked at $13K in Q4 2021. 136 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

  • Larson Financial Group reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Larson Financial Group sold 1 Arcturus Therapeutics share in Q3 2025, an estimated $13.
  • Larson Financial Group first reported a position in Arcturus Therapeutics in Q4 2021 and held it in 8 quarters.
  • Larson Financial Group's Arcturus Therapeutics position peaked at $13K in Q4 2021.
  • 136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on Larson Financial Group's 13F filing for Q3 2025, filed 14 Nov 2025.